This archived news story is available only for your personal, non-commercial use. Information in the story may be outdated or superseded by additional information. Reading or replaying the story in its archived form does not constitute a republication of the story.
CHICAGO, Jun 10, 2003 (United Press International via COMTEX) -- A study of African-American stroke patients indicates aspirin is as effective as ticlopidine for prevention of a second stroke.
The study involving 1,809 African American stroke patients from more than 60 sites in the United States was sponsored by the National Institute of Neurological Disorders and Stroke (NINDS).
Originally scheduled to run until October 2003, the research was halted in July 2002 after analyses suggested there was less than a 1 percent chance that ticlopidine would be shown to be superior to aspirin if the study were carried to completion.
Looking at the results of previous trials of ticlopidine, a type of clot inhibitor, investigators initially thought there was a strong possibility the agent would be safer and more effective than aspirin in African Americans with a history of stroke. That proved to be incorrect.
Results of the African American Antiplatelet Stroke Prevention Study (AAASPS) were published Tuesday in the Journal of the American Medical Association.
Copyright 2003 by United Press International.